Schrodinger 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Schrödinger reported 3rd quarter 2026 ACV of $44.7 million, up 17% year over year and up 24% excluding contribution ACV; trailing 4-quarter ACV was $214 million.
- Total revenue was $64.5 million, up 19%; software revenue was $38.2 million, including hosted revenue of $17.2 million, up 49%. Hosted revenue was 45% of software revenue versus 32% in the 3rd quarter of 2025.
- Drug discovery revenue was $24.2 million versus $13 million in Q3 2025, primarily due to a milestone payment associated with Structure Therapeutics' oral amylin program.
- Software gross margin was 75% versus 77% in Q3 2025. Operating expenses were $64 million, down 13% from $74 million in Q3 2025; net loss was $38 million versus $33 million.
- Schrödinger ended the quarter with $373 million in cash and marketable securities and a fully diluted share count of 74.9 million.
- Bunsen, Schrödinger's agentic AI co-scientist, was the primary interface for internal discovery workflows and handled approximately 80% of high-throughput calculations on the company's internal compute cluster.
- Predictive toxicology can now evaluate more than 80 potential off-target proteins computationally, and the solution contributed to ACV this year.
- Schrödinger launched Tectora, funded with $55 million from NEA and RA Capital, around 2 programs originated by its therapeutics team; the company received equity and is eligible for milestones and royalties.
- Takeda's New Drug Application for zasocitinib was accepted under Priority Review. Schrödinger also reported clinical progress for Structure's ACCG-2671, Morphic's zotemtagrast, and its MALT1 inhibitor Xylem Maltib (SGR1505).
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Hello, everyone. Thank you for joining us, and welcome to Schrödinger's conference call to review third quarter 2026 financial results. After today's prepared remarks, we will host a question-and-answer session. If you would like to ask a question, please press star one to raise your hand. To withdraw your question, please press star one again. Please be advised that this call is being recorded at the company's request. Now, I would like to introduce your host for today's conference, Ms. Jaren Madden, Chief Corporate Affairs Officer and Head of Investor Relations.
Please go ahead. Thank you, and good afternoon, everyone.
Welcome to today's call, during which we will provide an update on the company and review our third quarter 2026 financial results. Earlier today, we issued a press release summarizing our financial results and progress across the company, which is available on our website at schrodinger.com. During today's call, management will make statements that are forward-looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements related to our outlook for the full year 2026, our plans to accelerate the growth of our software business and advance our therapeutics portfolio, the capability and potential advantages of Bunsen, our agentic AI co-scientist, the clinical potential and properties of our compounds and those of our collaborators, the use of our cash resources, as well as our future expenses.
These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies, and prospects, which are based on the information currently available to us and on assumptions we have made. Actual results may differ materially due to a number of important factors, including the considerations described in the risk factor section and elsewhere in the filings we make with the SEC, including our Form 10-Q for the quarter ended September 30, 2026. These forward-looking statements represent our views only as of today, and we caution you that, except as required by law, we may not update them in the future, whether as a result of new information, future events, or otherwise. Also included in today's call are certain non-GAAP financial measures.
These non-GAAP financial measures are not prepared in accordance with generally accepted accounting principles and should be considered only in addition to and not a substitute for or superior to GAAP measures. Please refer to the tables at the end of our press release, which is available on our website, for reconciliations of these non-GAAP measures to the most directly comparable GAAP measures. This afternoon, Ramy Farid, our CEO, will review our recent progress. Richie Jain, Chief Financial Officer, will discuss our financial results and 2026 guidance. Karen Akinsanya, President, Head of Therapeutics R&D, and Chief Strategy Officer Partnerships, will provide an update on our therapeutics portfolio. Pat Lorton, our Chief Technology and Chief Operating Officer, will join us for the Q&A. With that, I will turn the call over to Ramy.
Thanks, Jaren, and thank you, everyone, for joining us today. Our third quarter results reflect sustained commercial momentum and strong progress toward the long-range goals we outlined earlier this year. ACV grew 17%, or 24% excluding contribution ACV. The key drivers of this growth were broader adoption within large pharmaceutical accounts, the introduction of new products, including Bunsen, our agentic AI co-scientist, growth among biotech and material science customers, and addition of new customers. Our discovery team continues to generate and contribute to high-value programs, which our partners and co-founded companies will advance through clinical development. During the quarter, we received a milestone payment associated with the clinical progress of Structure Therapeutics' oral small molecule amylin program. On the strength of this performance, we are raising our full-year guidance for both ACV and drug discovery revenue.
Looking across the molecular discovery landscape, biopharma and materials organizations are increasingly shifting toward a predict-first computational approach to increase the probability of success and shorten discovery timelines. As industries prioritize spending on the most high-impact solutions, our platform remains critical to molecular discovery, enabling us to deliver durable growth. While the promise of AI in molecular discovery is immense, models remain fundamentally constrained by the quality of their training data. Our competitive advantage lies in first principles, physics simulations that generate the accurate ground truth data needed to train truly predictive AI models. With the introduction of Bunsen, we are now deploying agentic AI to orchestrate our computational platform to increase efficiency and broaden user adoption across life sciences and material science.
Customer interest has been very strong, and the feedback from our early access program has been enthusiastically positive, with multiple customers in the process of evaluating the solution. Within Schrödinger, Bunsen has rapidly become the primary interface for discovery workflows and now handles approximately 80% of our high-throughput calculations on our internal compute cluster. Our predictive toxicology solution also continues to be an important part of our strategy to expand the capabilities of our platform. Moving from traditional safety testing to computational screening represents a significant paradigm shift that can save time and increase the probability of success. We are continuing to scale the scope of our predictive toxicology solution and can now evaluate more than 80 potential off-target proteins computationally. Commercial evaluations are progressing well.
We expect the adoption curve to follow the path of our foundational tools like FEP+, where thorough customer benchmarking requires diligence upfront, but ultimately establishes deeply integrated, highly entrenched software adoption that endures as the industry standard. We are very pleased with the progress we are making in material science. Customers across a broad range of industries, including chemicals, energy storage, semiconductors, and electronics, are increasing their use of our platform. By using our platform, scientists can accurately predict critical properties such as stability, conductivity, and mechanical performance prior to physical testing. Material science is an important long-term growth driver that significantly expands our software market beyond drug discovery. We continue to make scientific advancements in this area. Last month, we published breakthrough research in Nature that revealed critical insights in the fundamental chemistry of lithium batteries.
Using our machine learning force fields, our team simulated battery electrolytes at unprecedented accuracy, paving the way for the computational design of higher capacity, faster charging, and longer-lasting batteries. Additionally, our researchers recently published a novel method for accurately predicting the stability of organic electronic materials for OLED displays. These advancements highlight how our platform enables materials innovators to replace experimental trial and error with rapid, predictive computational design. We are pleased to see continued success across our collaborative portfolio as partnered assets reach important clinical and regulatory milestones. Takeda's new drug application for zasocitinib, the TYK2 inhibitor we co-invented with Nimbus, was accepted under Priority Review. Approval is expected early next year, further reinforcing our track record of success. During the quarter, we launched Tectora, a discovery stage company funded with $55 million for NEA and RA Capital, and anchored by two programs originated by our therapeutics team.
Tectora is the latest company built through our co-founding strategy, which has already produced a number of clinical successes and allows us to share in long-term value through equity, milestones, and royalties. We feel confident about the direction of the company and our momentum heading into the end of the year. Tackling complex computational challenges takes immense dedication, and I want to thank our entire team for their hard work. I'll now turn the call over to Richie to review our financial results.
Thank you, Rami, and good afternoon. Our third quarter results highlight the ongoing momentum across our business, marked by strong ACV growth, continued transition to hosted licenses, progress in our drug discovery business, and disciplined expense management. Third quarter ACV was $44.7 million, which represents 17% growth year-over-year and $214 million on a trailing four-quarter basis. Third quarter growth, excluding contribution ACV, was 24%. ACV growth was broad-based, driven by our top 20 pharma customers, as well as biotech and materials science customers. Total revenue for the third quarter of 2026 was $64.5 million, a 19% increase. Software revenue was $38.2 million, of which hosted revenue was $17.2 million, a 49% increase. Hosted revenue represented 45% of the software total, compared to 32% in the third quarter of 2025. On a trailing four-quarter basis, hosted revenue increased to 32% of the software total from 23% in Q3 2025.
We are pleased with our progress in transitioning customers to hosted licensing. As a reminder on revenue recognition, transitioning customers from on-premise to hosted licensing temporarily moderates our reported software revenue because hosted contracts are recognized ratably over the life of the contract. Every 1% increase in hosted revenue results in an approximate $2 million-$3 million reduction in reported revenue, depending on contract length and renewal timing. Software gross margin was 75% for the quarter, compared to 77% in Q3 2025, reflecting our ongoing transition to hosted software licensing. Drug discovery revenue was $24.2 million, compared to $13 million in Q3 2025. The increase was primarily driven by a milestone payment associated with Structure's oral amylin program. Total operating expenses for Q3 were $64 million, a decrease of 13% compared to $74 million in Q3 2025. The decrease was primarily driven by lower clinical CRO costs and headcount-related expenses.
Total other expense was $11.4 million, primarily due to changes in the mark-to-market value of our public equity positions. Net loss for the quarter was $38 million, compared to $33 million in the third quarter of 2025. We ended the quarter with $373 million in cash and marketable securities. The fully diluted share count was 74.9 million. Turning to our full year 2026 guidance. We now expect full year 2026 ACV to be in the range of $222 million-$232 million, representing 12%-17% growth over 2025, and reflecting our year-to-date performance and outlook for the remainder of the year. We now expect drug discovery revenue to be in the range of $75 million-$85 million, compared to our prior expectation of $65 million-$75 million, due to the recognition of a milestone payment from Structure. Our operating expenses are still expected to be less than 2025.
In summary, our third quarter results show that software demand is strong, our integrated business model is working, and our spending remains disciplined. With our excellent year-to-date progress and visibility into our fourth quarter, we have raised expectations for the full year and remain confident in our financial trajectory. I would now like to hand the call over to Karen to provide an update on our therapeutics portfolio.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
12 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
